Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the promotion of John Lunger to chief patient supply officer, from SVP, manufacturing and supply chain,

Read the full 504 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE